Suppr超能文献

癌症幸存者研究中癌症易感性基因种系致病性变异的频率。

Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study.

机构信息

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.

出版信息

JNCI Cancer Spectr. 2021 Jan 23;5(2). doi: 10.1093/jncics/pkab007. eCollection 2021 Apr.

Abstract

BACKGROUND

Pediatric cancers are the leading cause of death by disease in children despite improved survival rates overall. The contribution of germline genetic susceptibility to pediatric cancer survivors has not been extensively characterized. We assessed the frequency of pathogenic or likely pathogenic (P/LP) variants in 5451 long-term pediatric cancer survivors from the Childhood Cancer Survivor Study.

METHODS

Exome sequencing was conducted on germline DNA from 5451 pediatric cancer survivors (cases who survived ≥5 years from diagnosis; n = 5105 European) and 597 European cancer-free adults (controls). Analyses focused on comparing the frequency of rare P/LP variants in 237 cancer-susceptibility genes and a subset of 60 autosomal dominant high-to-moderate penetrance genes, for both case-case and case-control comparisons.

RESULTS

Of European cases, 4.1% harbored a P/LP variant in high-to-moderate penetrance autosomal dominant genes compared with 1.3% in controls (2-sided  = 3 × 10). The highest frequency of P/LP variants was in genes typically associated with adult onset rather than pediatric cancers, including , , , , and . A statistically significant excess of P/LP variants, after correction for multiple tests, was detected in patients with central nervous system cancers (, , , ), Wilms tumor (, ), non-Hodgkin lymphoma (), and soft tissue sarcomas (, , , , ) compared with other pediatric cancers.

CONCLUSION

In long-term pediatric cancer survivors, we identified P/LP variants in cancer-susceptibility genes not previously associated with pediatric cancer as well as confirmed known associations. Further characterization of variants in these genes in pediatric cancer will be important to provide optimal genetic counseling for patients and their families.

摘要

背景

尽管儿童癌症的总体生存率有所提高,但儿科癌症仍是导致儿童死亡的主要疾病原因。胚系遗传易感性对儿科癌症幸存者的影响尚未得到广泛描述。我们评估了来自儿童癌症幸存者研究的 5451 名长期儿科癌症幸存者中 5451 名个体的胚系遗传中致病性或可能致病性(P/LP)变异的频率。

方法

对 5105 名欧洲裔儿科癌症幸存者(诊断后至少存活 5 年的病例)和 597 名欧洲无癌成年人(对照)的胚系 DNA 进行外显子组测序。分析侧重于比较 237 个癌症易感性基因和 60 个常染色体显性高至中度外显率基因的罕见 P/LP 变异在病例-病例和病例对照比较中的频率。

结果

在欧洲裔病例中,与对照组的 1.3%相比,高至中度外显率常染色体显性基因中存在 P/LP 变异的比例为 4.1%(双侧=3×10)。P/LP 变异的最高频率发生在通常与成人发病而不是儿科癌症相关的基因中,包括、、、、和。在中枢神经系统癌症(、、、)、Wilms 瘤(、)、非霍奇金淋巴瘤()和软组织肉瘤(、、、、)患者中,校正多重检验后,检测到 P/LP 变异的频率明显高于其他儿科癌症患者。

结论

在长期儿科癌症幸存者中,我们发现了先前与儿科癌症无关的癌症易感性基因中的 P/LP 变异,以及确认了已知的关联。对这些基因中的变异进行进一步的儿科癌症特征分析对于为患者及其家属提供最佳遗传咨询将是重要的。

相似文献

1
Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study.
JNCI Cancer Spectr. 2021 Jan 23;5(2). doi: 10.1093/jncics/pkab007. eCollection 2021 Apr.
2
A Genome-First Approach to Characterize DICER1 Pathogenic Variant Prevalence, Penetrance, and Phenotype.
JAMA Netw Open. 2021 Feb 1;4(2):e210112. doi: 10.1001/jamanetworkopen.2021.0112.
3
Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma.
JAMA Oncol. 2020 May 1;6(5):724-734. doi: 10.1001/jamaoncol.2020.0197.
4
Frequency of pathogenic germline variants in pediatric medulloblastoma survivors.
Front Oncol. 2024 Aug 9;14:1441958. doi: 10.3389/fonc.2024.1441958. eCollection 2024.
5
Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma.
JCO Precis Oncol. 2021 Jan 11;5. doi: 10.1200/PO.20.00218. eCollection 2021.
7
Somatic and Germline Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors.
Clin Cancer Res. 2017 Apr 1;23(7):1852-1861. doi: 10.1158/1078-0432.CCR-16-0610. Epub 2016 Sep 28.
8
Genetic Risk for Subsequent Neoplasms Among Long-Term Survivors of Childhood Cancer.
J Clin Oncol. 2018 Jul 10;36(20):2078-2087. doi: 10.1200/JCO.2018.77.8589. Epub 2018 May 30.
10
Rare germline variants in childhood cancer patients suspected of genetic predisposition to cancer.
Genes Chromosomes Cancer. 2022 Feb;61(2):81-93. doi: 10.1002/gcc.23006. Epub 2021 Oct 30.

引用本文的文献

2
Patients with Papillary Renal Cancer and Germline Duplication of Exons 5-21.
Biomedicines. 2025 May 29;13(6):1329. doi: 10.3390/biomedicines13061329.
3
TTN and BAG3 in Cancer Therapy-Related Cardiomyopathy Among Long-Term Survivors of Childhood Cancer.
JAMA Netw Open. 2025 Jun 2;8(6):e2515793. doi: 10.1001/jamanetworkopen.2025.15793.
4
Genetic predisposition in sarcomas: clinical implications and management.
EClinicalMedicine. 2025 Apr 15;83:103203. doi: 10.1016/j.eclinm.2025.103203. eCollection 2025 May.
5
Hodgkin lymphoma and Ewing sarcoma in pediatric patient carrying germline variant: a case report and literature review.
Front Oncol. 2025 Feb 18;15:1514697. doi: 10.3389/fonc.2025.1514697. eCollection 2025.
6
Germline Pathogenic DROSHA Variants Are Linked to Pineoblastoma and Wilms Tumor Predisposition.
Clin Cancer Res. 2025 Apr 14;31(8):1491-1503. doi: 10.1158/1078-0432.CCR-24-2785.
8
Genetic and epigenetic bases of long-term adverse effects of childhood cancer therapy.
Nat Rev Cancer. 2025 Feb;25(2):129-144. doi: 10.1038/s41568-024-00768-6. Epub 2024 Nov 7.

本文引用的文献

4
Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma.
JAMA Oncol. 2020 May 1;6(5):724-734. doi: 10.1001/jamaoncol.2020.0197.
5
Cancer statistics, 2020.
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
6
Estimated number of adult survivors of childhood cancer in United States with cancer-predisposing germline variants.
Pediatr Blood Cancer. 2020 Feb;67(2):e28047. doi: 10.1002/pbc.28047. Epub 2019 Nov 17.
7
Association of Germline BRCA2 Mutations With the Risk of Pediatric or Adolescent Non-Hodgkin Lymphoma.
JAMA Oncol. 2019 Sep 1;5(9):1362-1364. doi: 10.1001/jamaoncol.2019.2203.
9
Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.
J Natl Cancer Inst. 2019 Jan 1;111(1):95-98. doi: 10.1093/jnci/djy147.
10
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
N Engl J Med. 2018 Aug 23;379(8):753-763. doi: 10.1056/NEJMoa1802905. Epub 2018 Aug 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验